OTCMKTS:CHGCY Chugai Pharmaceutical 10/25/2024 Earnings Report $21.45 -0.10 (-0.46%) As of 03:59 PM Eastern ProfileEarnings HistoryForecast Chugai Pharmaceutical EPS ResultsActual EPS$0.22Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AChugai Pharmaceutical Revenue ResultsActual Revenue$2.12 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AChugai Pharmaceutical Announcement DetailsQuarterDate10/25/2024TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsChugai Pharmaceutical's next earnings date is estimated for Friday, October 23, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Chugai Pharmaceutical Earnings HeadlinesChugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Short Interest Down 54.9% in JulyAugust 15 at 4:31 AM | americanbankingnews.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.August 17 at 1:00 AM | Investors Alley (Ad)Chugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call TranscriptJanuary 29, 2026 | seekingalpha.comChugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DMENovember 25, 2025 | finanznachrichten.deChugai Pharmaceutical to Merge with Renalys Pharma to Boost Kidney Disease Drug DevelopmentNovember 18, 2025 | msn.comSee More Chugai Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email. Email Address About Chugai PharmaceuticalChugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support. Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics. One of its best-known products is tocilizumab (marketed in many territories through collaborative arrangements), reflecting the company’s capabilities in immunology and antibody engineering. Chugai’s product portfolio and pipeline include both in-house assets and programs developed in collaboration with external partners, demonstrating a mix of internal R&D and strategic alliances to advance new medicines. Chugai maintains a long-standing strategic partnership with the Roche Group and operates primarily in the Japanese market while leveraging global commercialization channels through alliances. The company supports clinical development and manufacturing activities in Japan and engages with international partners to expand the reach of its therapies. Chugai is managed by a professional leadership and scientific team with experience in pharmaceutical R&D and commercial operations, and it positions itself as a research-oriented company within the global biopharmaceutical landscape.View Chugai Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Birkenstock Beats the Skeptics—But Not on EPSThese 5 Dividend Stocks Show Why Income Investing Still MattersThe Quantum Race Is Heating Up—And 2 Small Players Stand OutMarketBeat Week in Review – 08/10 - 08/14Applied Materials Beat Everything but Wall Street’s Expectations for MarginsLooking Beyond CrowdStrike? 3 AI Security Stocks Stand Out5 Recession-Proof Stocks Hiding in Cardboard Boxes Upcoming Earnings Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026)Alibaba Group (8/20/2026)Ross Stores (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
